These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22498572)

  • 1. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy.
    de Andrade DA; Machiels JP
    Curr Opin Oncol; 2012 May; 24(3):211-7. PubMed ID: 22498572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
    Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
    J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
    Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
    Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
    Yokota T; Onozawa Y; Boku N; Hamauchi S; Tsushima T; Taniguchi H; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Jpn J Clin Oncol; 2011 Dec; 41(12):1351-7. PubMed ID: 21980053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
    Machiels JP; Licitra LF; Haddad RI; Tahara M; Cohen EE
    BMC Cancer; 2014 Jun; 14():473. PubMed ID: 24973959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options for metastatic head and neck cancer.
    Price KA; Cohen EE
    Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck.
    Frampton JE
    Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.
    Machiels JP; Subramanian S; Ruzsa A; Repassy G; Lifirenko I; Flygare A; Sørensen P; Nielsen T; Lisby S; Clement PM
    Lancet Oncol; 2011 Apr; 12(4):333-43. PubMed ID: 21377930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Mesía R; Rivera F; Kawecki A; Rottey S; Hitt R; Kienzer H; Cupissol D; De Raucourt D; Benasso M; Koralewski P; Delord JP; Bokemeyer C; Curran D; Gross A; Vermorken JB
    Ann Oncol; 2010 Oct; 21(10):1967-1973. PubMed ID: 20335368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
    Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy for patients with local-regional recurrent or metastatic carcinoma of the head and neck].
    Dufresne A; Gainet M; Stein U; Guardiola E; Pivot X
    Bull Cancer; 2003 Jan; 90(1):39-45. PubMed ID: 12609803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
    Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
    Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
    Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
    J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Hitt R; Irigoyen A; Cortes-Funes H; Grau JJ; García-Sáenz JA; Cruz-Hernandez JJ;
    Ann Oncol; 2012 Apr; 23(4):1016-22. PubMed ID: 21865152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
    Knoedler M; Gauler TC; Gruenwald V; Matzdorff A; Schroeder M; Dietz A; Jordan WO; Arnold D; Hennemann B; Hofele C; Weissinger F; Eberhardt W; Keilholz U
    Oncology; 2013; 84(5):284-9. PubMed ID: 23445718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.
    Massa E; Dessì M; Gaspardini G; Saba F; Cherchi V; Mantovani G
    Oral Oncol; 2010 Nov; 46(11):818-21. PubMed ID: 20920877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.